Regen Biopharma Inc (PK) (RGBP) Quote

I'll roll the dice and say that never happened. The dude is still working on getting funding for this IND from 10 years ago. Clearly, he failed that dissertation. 😆

I mean, does the 10 minute video conference calls not give you a glimpse as to what he would be like "telemarketing?" 🤣

On a side note, here is a testimonial from AIU on their website from Koos:

https://www.aiu.edu/testimonials/david-r-koos-venture-bridge-managing-director/

Well think about what we might be missing. His thesis showed how biotechs like Amgen and Regeneron were actually funded by telemarketing, and ended up where they are today! Imagine all those late night cold calls to Grandmothers, who sent in their $50 money orders and seeded these companies that became mainstays in the drug world!

I wouldn't be surprised if Koos himself states that he was involved in this, on the ground floor, working the lines.

Who needs to read it.... we are living it. 🤣

Thanks, since he went to an uncredited online "University" (the pink sheet equivalent of education), likely they don't participate in posting such great works as Mr Koos online. It likely would be an embarrassment anyway. I searched for both thesis and dissertation.

PhD theses are generally publicly available and searchable—especially in the U.S., U.K., Canada, and many other countries with open academic publishing norms. Here’s how it typically works:

🔍 Where PhD theses are usually found:
University Repositories
Most universities require PhD candidates to deposit their dissertation in a digital repository (e.g., Harvard DASH, MIT DSpace, etc.), which are indexed and searchable online.

ProQuest Dissertations & Theses
In the U.S., ProQuest is a massive database of theses and dissertations. Many American universities submit all PhD theses here. Access may require a subscription, but basic search is open.

Google Scholar / WorldCat / Open Access Repositories
Some theses also appear here, especially if the author has uploaded them to academic sharing platforms like Academia.edu or ResearchGate.



I was unable to locate a publicly available PhD thesis titled "Examining the Efficacy of Telemarketing Fundraisers as a Venture Capital Alternative in the Biotechnology Industry: A Case Study of Cell Bio-Systems, Inc" authored by David Koos in major academic databases or repositories. This specific work does not appear in platforms such as arXiv or Taylor & Francis, and there are no publicly available records indicating its publication.

?I was unable to locate a published paper titled "Examining the Efficacy of Telemarketing Fundraisers as a Venture Capital Alternative in the Biotechnology Industry: A Case Study of Cell Bio-Systems, Inc" authored by David Koos in major academic databases or repositories.

If this thesis exists, it might be an internal report, a conference presentation, or a document with limited distribution. To pursue further information, you might consider:

Contacting Cell Bio-Systems, Inc.: They may have archives or records of internal studies or reports.?

Reaching out to David Koos directly: If he is affiliated with an institution or organization, they might provide contact information or access to his publications.?

Exploring business registries or press releases: Sometimes, companies release summaries or findings of studies in press releases or business filings.

I only read the dissertation title a long time ago. It’s located in some of the SEC reports filed.

Never found the actual paper.

Here is the actual title:

Examining the Efficacy of Telemarketing Fundraisers as a Venture Capital Alternative in the Biotechnology Industry: A Case Study of Cell Bio-Systems, Inc

Investing in pinks sheets largely is about making unfounded jump the gun readings into company statements that are so extreme that they amount to pure fiction.

This idea of a buyout being "indicated" by that statement is one of my top 10 ever!

I've said 100 times, there is a price to pay for using imagination and wishful thinking instead of facts when investing... the price is losses, which are proper and just, just like the +95% decline here.

You know, I've been looking for anything published by him for his non accredited college degrees, but have yet to find this. Do you have a link?

I still chuckle when I read the dissertation title to his "PhD" paper on "telemarketing fundraisers on venture capital."

If you type into a search engine "David Koos" the first "suggestion" comes up with "David Koos fraud." 🤣

What a masterpiece.

I still chuckle when I read the dissertation title to his "PhD" paper on "telemarketing fundraisers on venture capital."

That fits perfect for the garbage "PR's" he uses for his shareholders. Talk about funding capital through telemarketing in the OTC. 🙄🤣

That doesnt apply in WallStreet honey AND much less at OTCM… Thats a very naive statement in this field; wrong place to bring that up… Chuckles

Did you really believe on his buyout response? Chuckles… Heck no…. Koos will pass this sucking blood business when he is done, to his heir. Endless dilution, we are the cow

Mate!!! You did reply to me with that nonsense back in 2022… Could you share any advancement on your buyout speculation response?

Wait dont bother, I can help: NONE

Didnt I tell you what he was trying to do?

I told you so

I learned a long time ago that being a pessimistic person is way better on the mind, body and soul. My philosophy is, if you are already negative about everything then it can't get worse. If it becomes positive, then you just won.

Stupid simple. 🤣

There are three (3) principles I live by:

1. I watch lazy people to find the easiest and most efficient way to do things.
2. I listen to negative people before starting something to find out all the ways it could go badly.
3. And I learn from stupid people who teach me what not to do.

Yes, anyone that took a look a a 5 year history here (something that no shareholder here has ever done), you can see he just jumps from working on drug to drug, each time it is because the other one suddenly has a better business case.

This is the same thing as the "biotech" trick called "screening platform acquisition" in the OTC. A ticker will "acquire" a "screening platform," call themselves a "biotech" company and never actually produce anything other than "data" and then write about it. The idea is a biotech never needs to make revenues and only has to produce fluff PR's to keep shareholders motivated.

It's the same thing Koos is doing with bouncing back and fourth here. It's simple, effective and keeps the "company" alive.

The video conference calls are always hilarious. 10 minutes of him sitting in a chair in a room painted with white walls only where he keeps saying the same things as last year. 🤣

It still cracks me up that he writes in his annual reports that he rents a space from his own "realty company" and calls it his home/office/lab. I get the home/office but scientific research lab? 🤣

What are you working with a 1956 science kit?

Any updates on the buyout that was "indicated"?

Buyout Indicated, indirectly, in a previous 8k

Another example of the unlimited imagination of pink sheet investors! They can read positives into anything and everything!

There is a price for doing that though... losses, when reality hits.

You are one of the rare ones that see this for what it is and yes, the comedy factor is reason alone to follow.

Koos called off the last paid video conference call, which was scheduled to be only 10 minutes long, hours before it was to start, due to "bronchitis", which had me in stitches. The idea a CEO couldn't make it through a 10 minute call for that is just ridiculous.

Yes, anyone that took a look a a 5 year history here (something that no shareholder here has ever done), you can see he just jumps from working on drug to drug, each time it is because the other one suddenly has a better business case. I haven't posted all my recent findings, but he did try to run HemaXellerate through some central american testing, about 9 years ago, and like usual, for a while posted all the "great progress" (with zero data or proof) until either the results showed it was going nowhere, or he ran out of $. Now, years later, he's back with it, and if he gets some funding, best case, will run the same preliminary lab set up and simple early tests as he did 9 years ago, and pocket the rest of the offering $.

Just like you, I have a history of pink sheet CEOs changing their approach due to my posts. Good old Roxanna Weber of Emax used to say "soon" all the time, in answer to when things would be completed, a totally meaningless word. Well for months me and a few others would just post silly things about the answer being "soon", and ridiculing her. It became a running joke. Well after months of this, she instead started saying "in the very near term", which was a great compliment to me, and just as funny and pointless.

Thanks for the explanation.

My favorite part was:

Midstream in the "great progress" testing one of his drugs, he stopped dead on that testing, and went back to HemaXellerate, which had an IND like a decade ago, and he claims he is going to raise money to do a phase 1 test on it. The best part is that he did this ONLY after I submitted a question on his call, months ago, to embarrass him as to why he did nothing with this drug, 10 years after getting an IND! The next month he announced the shift back to HemaXellerate! (ping pong) So basically I am calling the shots here!

Nice work!

I had something similar on another ticker where I wrote these posts and the next day the "CEO" would magically write a "PR" on the exact things I pointed out! He even went as far as to copy and paste one post telling him how to run his business!

Comedy gold. Needless to say he gave up when I just kept pointing things out and "sold" the ticker. 🤣

This guy is definitely playing ping pong. In what world does someone create an IND, abandon it and then state he is bringing it back? If something was actually good then many "big pharma's" and even medium size would be interested in helping to fund it.

It seems he is still doing this "I'm working on funding" bit.

This is like real life Seinfeld. Only better.

Yes, I figured I would see if I could lure you back here! I miss seeing your posts here, and yes, I'm back.

Although post wise, seems like the cheerleaders for this scam are either in hiding or licking their wounds, the Koos scam still continues!

Well you might have missed that months after the reverse he paid a "dividend" which in effect undid part of the reverse. These additional shares were like throwing gasoline on a fire, and sent it lower. He knew that pink sheet investors see the word "dividend" and jump to the conclusion this means the company is growing. Instead, they got Koos'ed again!

Midstream in the "great progress" testing one of his drugs, he stopped dead on that testing, and went back to HemaXellerate, which had an IND like a decade ago, and he claims he is going to raise money to do a phase 1 test on it. The best part is that he did this ONLY after I submitted a question on his call, months ago, to embarrass him as to why he did nothing with this drug, 10 years after getting an IND! The next month he announced the shift back to HemaXellerate! (ping pong) So basically I am calling the shots here!

There is another video call next week where he will dance around this again, wanting to give people the impression his is making progress raising more money, yet still will not be going forward with any testing. Just lots of talk of "being excited". The over under on that phrase is about 5 per call!

Are my eyes deceiving me? Pumper Stumper? It's been a while......

You brought up a 2 year old post.... 🤣

I've been out of this thing for a long time.

Good to see you want a laugh still out of this "biotech."

I see the price is at 5 cents. I thought the stock was suppose to go up after that massive reverse split? What happened? 😆

He literally says he was to aggressive with the R/S then proceeds to say "get over it."

That's just great. I want to see if I can find that one!

Waiting for $0.01s to average down.

Some drama here. Does Koos sign up for the next conference April 16/17? Or does his "illness" continue! Stay tuned!

I had to re-read that. I thought you meant the CEO is heavier than us (which he most certainly is). Pink sheet CEO's always eat well on the shareholders dimes. Take a look at how many are very overweight.

That guy is healthier than us, he is not going nowhere and if he is, someone else will take over his Con-space. Let dilution and blood sucking continues.

Rgbp-Rgbpp : 🚨S.C.A.M ALERT🚨

Remember folks, a few of us exposed this scam 10+ years ago yet the pump and dumpers on here fooled a lot of you suckers into thinking this was a sure thing. How does it feel now to know that not only did you get scammed by the pump n dumpers on here, like 29IQinvestor who should be in jail for being a white collar message board criminal, but that you failed to heed our warnings? Now you have a huge capital gains loss. Koos is a white collar criminal using the OTC to subsidize his life style of italian sports cars and small boat yachting. I'm still waiting for that fat phuck to tell us what exactly his brother did for all that money he paid him? A good accountant will probably find that the payment wasn't for any work to be done but was paid to pay his brother back for a personal loan, imo.

Who said: " The market teaches expensive lessons, and has no sympathy. For those who continue to ignore facts, there are more declines coming, I PROMISE!"

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169149951

Since I was hear last, RGBP has (Split adjusted) fallen from $2.92, to $0.05 So down only 98% In just 15 months! And this after 90% declines from prior years! Sick! And Fun!

Nothing has changed except SOME of the long time shareholders with 99+% losses are starting to see the light! Is that all it takes to figure it out!

Once again, the market teaches expensive lessons. If you continue to invests in scams, the market will teach you expensive lessons! It still holds!

It's so joyful to see when markets work!

DD challenge: Koos chose ClinDatrix to do the Phase 1 trial for their 9 year mothballed "miracle drug" that he suddenly decided to resurrect.

Any good quality proper due diligence on ClinDatrix would show why these 2 pathetic companies are perfect for each other. Remember, this is the company they hand picked to do the work to move this through this phase's trial. My challenge is to post what you found on them. It should be easy, but you do need to do more than just google and rehash the words. You need to judge their past history What did you find? Not doing a proper job in this will result in... guess what... more losses here!

It was filed because Koos's auditor was a slimeball (similar types attract each other), and was banned from auditing by the SEC. The SEC notes show that basically this auditor would hardly look into things. In other words the perfect auditor for a pink sheet scam! The SEC required all companies that this auditor audited, to hire a REAL auditor and get re-audited. You know Koos won't stand and pay for a real audit!

As such they are no longer an audited company. Koos initially did try to hire a new auditor, but this new one was legitimate, so no way RGBP was going to pass without a lot of work/rework. So Koos stopped the audit and it's no longer even being pursued! (this is the pinks, who cares about being audited... he knows his audience! )

This means that they can no longer be an SEC reporting company, so he had no choice but to file a SEC 15 to cut ties with the SEC and get back to what all "quality" companies do, being alternative reporting via OTC Markets.

Today's presentation is cancelled! Time to better expose this scam! Today $RGBP had a 10 minute video presentation scheduled. Koos does these from his home office. You know, the one shareholders pay $5,000 a month rent for. Anyway, he posted on X today that he won't be participating due to "bronchitis".

Anyone who believes that likely also believe that RGBP was a good buy at $5.

https://www.facebook.com/share/r/15rNwaKvYo/?mibextid=eBqqwY

Reverse/splits in general are a waste of time and simply function to dilute the stock and decrease shareholder value.

pps 0.0765 / 1500(rs) = 0,000051 real pps

That RS really did this stock in, and took a lot of money from Us believers in this thing. What is the latest based on the below filing?

It took awhile , but it is where it was almost when the R/S took place . Koos and his scams
This phrase refers to a legal document, specifically "Form 15" filed with the Securities and Exchange Commission (SEC), which essentially signifies a company's certification that it is terminating its registration of a class of securities under Section 12(g) of the Securities Exchange Act of 1934, meaning they no longer need to file periodic reports because they have become a private company, or that they are suspending their duty to file reports under Sections 13 and 15(d) of the same act; effectively removing their public reporting obligations.
Key points about this phrase:
Form 15: This is the official SEC form used to make this notification.
Section 12(g): This section of the Securities Exchange Act outlines the requirements for a company to register its securities with the SEC and become subject to periodic reporting.
Sections 13 and 15(d): These sections dictate the specific reporting requirements that a public company must follow.
When a company might file this form:
When the number of shareholders of a publicly traded class of securities falls below a certain threshold, allowing them to "go private".
If a company is undergoing a merger or acquisition that results in a significant reduction in public shareholders.

Is Regen Biopharma going private?

Hmmm. Wonder why they filed this today:

https://www.sec.gov/Archives/edgar/data/1589150/000149315224052071/form15-15d.htm

Yes. The right faked scammy news that many unaware people are buying in and get defrauded. Koos should be indicted and jailed

You mean, "how can we pump n dump this like we have in the past?"

The history of this scam company with its unethical CEO, who made up fake tasks for his brother in order to pay the personal loan back he got from him back, sorta shows he is incompetent of doing anything positive. He is a scam artists using the rules of the OTC to fund his lifestyle of boating and buying and maintaining his expensive Italian sports car. He's a fraud. Odds are he isn't to get any significant funding for HemaX

With the right news,this could pop

The fat bastard CEO still hasn't shown he can do much to run a company. But, he is sure good at spending money on himself by boating and purchasing a Maserati. He can't even raise money to fund the P1 trial for HemaX now that he's done a complete 360 back to after abandoning it years ago and realizing he can't advance any of the other therapies. He and Loser Lander are are incompetent conmen. Heck, Koos is still showing "scientific" advisors that aren't advising him at all on his website to make it appear he has a competent team. That's just fraud.

We'll see. We'll see.

Regen BioPharma, Inc. Expands Vision for Phase 1 Clinical Trial of HemaXellerate

SAN DIEGO, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC Pink: RGBP and RGBPP) today provided further insight into its planned Phase 1 clinical trial of HemaXellerate™, the company’s innovative stem cell-derived therapy, which has already received FDA clearance. While the initial focus is on treating aplastic anemia, Regen BioPharma is evaluating expanded applications for this groundbreaking therapy in a market poised for significant growth.

HemaXellerate™ is designed to stimulate bone marrow regeneration following injury caused by autoimmune conditions, chemotherapy, or radiation. While the company’s initial target is aplastic anemia—a rare orphan indication—it sees substantial potential in treating chemotherapy-induced bone marrow suppression, a market valued at over $1 billion annually. This is evidenced by the success of products like Neulasta, which addresses similar unmet needs.

“Aplastic anemia patients without access to bone marrow transplantation face limited options,” said Dr. David Koos, Chairman and CEO of Regen BioPharma. “With FDA clearance to begin clinical trials, HemaXellerate™ has the potential to redefine the treatment landscape—not just for aplastic anemia but for a wide range of hematological disorders. This is a pivotal moment for our company as we work to deliver life-changing therapies to patients worldwide.”

To ensure the trial’s success, Regen BioPharma has partnered with a clinical research organization (CRO) known for its expertise in conducting complex trials. Once initiated, the study is expected to reach completion within 12 to 14 months.

Key Highlights for Investors:

Opportunity: Aplastic anemia is a rare disease with high unmet medical need, offering the potential for accelerated regulatory pathways and market exclusivity.

Massive Market Potential: Expansion into chemotherapy-induced bone marrow suppression could unlock a multi-billion-dollar market.

Strategic Execution: Collaboration with a leading CRO ensures focused execution and timeline adherence.

About Regen BioPharma, Inc.

Regen BioPharma, Inc. is a publicly traded biotechnology company (PINK: RGBP) and (PINK: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on mRNA and small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.

https://finance.yahoo.com/news/regen-biopharma-inc-expands-vision-210500940.html

https://www.otcmarkets.com/stock/RGBP/news/story?e&id=3052310

If the cancer part is accurate, this is where I potentially speaking see this shell to be finally acquired. Hopefully he finally let us go

I couldn't agree with you more on this.

where are you hearing this? Remember, he resigned as CEO of REGEN with no reason given and no one to take over for about a year before he came back. It was at that time the pump of the decade happened with the stock. I wouldn't be surprised if he did have some sort of health issues. He hasn't looked healthy.

Rumor has it that Kooscous has serious cancer and has gone to Tel Aviv for treatment. Incredibly, he used the medical field of cancer to swindle shareholders and karmic law punished him with a backlash.....
Boomerang !!!

Good luck with FINRA looking into it

That's FINRA's department.

Except in extremely rare cases, R/S are a scam. The SEC needs to make the rules more strict. Why is a company like Regen BioPharma with unaudited financials allowed to RS? There's no reason for it except to screw over shareholders.

I've never witnessed a reverse/split help matters for any stock long-term.

I just caught up with Konman Koos very informative vids from the emerging turd conferences he shows his fat face at. It is absolutely hilarious that they are trying to find funding for a P1 trial for HemaX. Funny how he did a 180. He abandoned HemaX long ago to push his other crap and those programs didn't go anywhere, he and Loser Lander had to go back to HemaX. It will be interesting to see if he can find a sucker to give him money to fund a P1 trial for HemaX. I don't think he's going to be lucky in finding another mark. Anyone doing their DD into Koos would realize he's a scam artist. Talking about scam artists, where is 29IQ?